CONSOLIDATED BALANCE SHEETS (USD $)	Sep. 30, 2011		Dec. 31, 2010
Current assets
Cash	$ 983,286		$ 238,565
Grants receivable			244,479
Prepaid drug product for testing			88,400
Other current assets	52,026		72,993
Total current assets	1,035,312		644,437
Other assets
Technology licenses - related party	3,106,368		3,043,821
Less Accumulated Amortization	(737,243)		(579,754)
Intangible Assets, Net (Excluding Goodwill), Total	2,369,125		2,464,067
TOTAL ASSETS	3,404,437		3,108,504
Current liabilities
Accounts payable	43,135		88,400
Accrued expense	111,862		84,141
Accrued license payments - related party	50,000		74,217
Total current liabilities	204,997		246,758
Long term debt
TOTAL LIABILITIES	204,997		246,758
Shareholders' Equity
Preferred Stock, $.001 par value 10,000,000 shares authorized, no shares issued and outstanding
Common Stock, $.001 par value, 200,000,000 shares authorized 56,146,296 and 49,400,605 shares issued and outstanding as of 9/30/11 and 12/31/10, respectively	56,146		49,401
Additional paid in capital	11,745,990		9,719,147
Additional paid in capital for shares to be issued	142,000	[1]	278,600	[2]
Accumulated deficit during development stage	(8,744,696)		(7,185,402)
Total shareholders' equity	3,199,440		2,861,746
TOTAL LIABILITIES & SHAREHOLDERS' EQUITY	$ 3,404,437		$ 3,108,504

[1] Represents 473,334 shares of common stock

[2] Represents 928,667 shares of common stock